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A B S T R A C T
The measurement of bisphenol-S (BPS) and its glucurono-conjugate (BPSG) in urine may be used for the bio-
monitoring of exposure in populations. However, this requires a thorough knowledge of their toxicokinetics. The
time courses of BPS and BPSG were assessed in accessible biological matrices of orally and dermally exposed
volunteers. Under the approval of the Research Ethics Committee of the University of Montreal, six volunteers
were orally exposed to a BPS-d8 deuterated dose of 0.1 mg/kg body weight (bw). One month later, 1 mg/kg bw
of BPS-d8 were applied on 40 cm2 of the forearm and then washed 6 h after application. Blood samples were
taken prior to dosing and at fixed time periods over 48 h after treatment; complete urine voids were collected
pre-exposure and at pre-established intervals over 72 h postdosing. Following oral exposure, the plasma con-
centration–time courses of BPS-d8 and BPSG-d8 over 48 h evolved in parallel, and showed a rapid appearance
and elimination. Average peak values (± SD) were reached at 0.7 ± 0.1 and 1.1 ± 0.4 h postdosing and mean
(± SD) apparent elimination half-lives (t½) of 7.9 ± 1.1 and 9.3 ± 7.0 h were calculated from the terminal
phase of BPS-d8 and BPSG-d8 in plasma, respectively. The fraction of BPS-d8 reaching the systemic circulation
unchanged (i.e. bioavailability) was further estimated at 62 ± 5% on average (± SD) and the systemic plasma
clearance at 0.57 ± 0.07 L/kg bw/h. Plasma concentration–time courses and urinary excretion rate profiles
roughly evolved in parallel for both substances, as expected. The average percent (± SD) of the administered
dose recovered in urine as BPS-d8 and BPSG-d8 over the 0–72 h period postdosing was 1.72 ± 1.3 and
54 ± 10%. Following dermal application, plasma levels were under the lower limit of quantification (LLOQ) at
most time points. However, peak values were reached between 5 and 8 h depending on individuals, suggesting a
slower absorption rate compared to oral exposure. Similarly, limited amounts of BPS-d8 and its conjugate were
recovered in urine and peak excretion rates were reached between 5 and 11 h postdosing. The average percent
(± SD) of the administered dose recovered in urine as BPS-d8 and BPSG-d8 was about 0.004 ± 0.003 and
0.09 ± 0.07%, respectively. This study provided greater precision on the kinetics of this contaminant in hu-
mans and, in particular, evidenced major differences between BPA and BPS kinetics with much higher systemic
levels of active BPS than BPA, an observation explained by a higher oral bioavailability of BPS than BPA. These
data should also be useful in developing a toxicokinetic model for a better interpretation of biomonitoring data.
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1. Introduction
Bisphenol S, bis(4-hydroxyphenyl) sulfone (BPS), is a substance
synthesized from the sulfonating of phenols (Johannes, 2014). It is
ubiquitous in the environment (Liao et al., 2012; Wan et al., 2018). BPS
was synthesized for the first time in 1869, and it began to be used as a
substitute to its analogue bisphenol A (BPA) in the years 2000 s
(Glausiusz, 2014). BPS has a widespread commercial and consumer use.
BPS is used as an intermediate for the production of epoxy resins and
polycarbonate plastics; it is present in a variety of industrial products
(e.g. cleaning products), food (e.g. meat, dairy products) and personal
care products (e.g. body and hair products) (Rochester and Bolden,
2015; Viñas et al., 2010; Wu et al., 2018). It is also used as a developer
in thermal papers (tickets), providing thermosensitive properties
(ANSES, 2013). The general population can therefore be exposed
through ingestion of contaminated food but also dermal contact (Chen
et al., 2016; Wu et al., 2018).
Given that BPA has been shown to have endocrine disrupting
properties, some authors have also assessed the estrogenic potencies of
BPS in vitro and in vivo in animals (Chen et al., 2016; Rochester and
Bolden, 2015). As observed for BPA, the latter reviews highlight that
BPS is hormonally active, showing estrogenic activities in rats, zebra-
fish and Daphne magna in vivo, and oestrogenic and antiandrogenic
potencies in vitro. Furthermore, according to Kojima et al. (2019), BPS
showed agonist activities for human estrogen receptors (ERα and ERß)
in the same order of magnitude as BPA. In an in vivo study in female
rats, Ahsan et al. (2018) also showed that BPS altered estrus cycle and
ovarian function and development.
According to metabolism studies in animals, BPS is readily con-
jugated to glucuronides once absorbed in the body, similar its BPA
analogue. Free BPS is considered the active moiety, while the detox-
ification product BPS-glucuronide (BPSG) has been documented to be
the main compound excreted in urine (Gayrard et al., 2019a; Gayrard
et al., 2019b; Grandin et al., 2018). In humans, there is a growing body
of literature on exposure to BPS in the general population, as assessed
from measurements of BPS and BPSG in accessible matrices
(Frederiksen et al., 2020; Ghayda et al., 2019; Husøy et al., 2019;
Lehmler et al., 2018; Liao et al., 2012; Liu et al., 2017; Ndaw et al.,
2018; Philips et al., 2018; Wan et al., 2018; Ye et al., 2015). In parti-
cular, Liao et al. (2012) was the first study to report BPS levels in the
general population; they showed that total BPS (the sum of free and
glucurono-conjugated BPS) was detectable in 81% of spot urine samples
(n = 315) collected in Americans and Asians (Chinese, Indians, Japa-
nese, Korean, Kuwait, Malaysian and Vietnamese) aged 2 to 84 years
old, with geometric mean concentrations of 0.168 µg/L (range of LOQ
of 0.02 to 21 µg/L). Liu et al. (2017) also measured total BPS in 61
paired maternal and cord blood samples from the Chinese population.
Although total BPS was detectable only in 4 maternal and 7 cord blood
samples, with a range of < 0.03 to 0.07 µg/L, this study showed that
BPS can cross the human placenta. More recently, Ndaw et al. (2018)
measured total BPS in pre- and post-shift urine samples and first
morning void of 17 French cashiers and 15 controls; they found that
concentration values were significantly higher in cashiers compared to
controls (geometric mean (range) of 2.48 (0.1–28.4 µg/L) versus
0.72 µg/L (< LOQ of 0.1–229 µg/L)). Lehmler et al. (2018) analyzed
total BPS concentrations in spot urine samples of children (n = 868)
and adults (n = 1808) participating in the National Health and Nu-
trition Examination Survey (NHANES) 2013–2014; total BPS was de-
tected in 89.4% of samples with median concentration of 0.37 µg/L in
adults (interquartile of 0.14–0.88 µg/L) and 0.29 (0.12–0.70) µg/L in
children. In a prospective cohort of Netherland females enrolled during
early pregnancy (n = 1396), Philips et al. (2018) reported a detection
rate of total BPS of 67.8% in spot urine samples collected in 2004–2005
and median concentrations of 0.36 µg/L (interquartile of 0.17–1.08 µg/
L), similar to results in NHANES participants. Ghayda et al. (2019) also
documented semen and urinary concentrations of total BPS in 158 men
enrolled in a prospective cohort in Massachusetts (USA) and seeking
fertility treatment from 2011 to 2017, and reported a 76% detection
rate (> 0.1 µg/L) from 338 urine samples, a geometric mean of
0.37 µg/L and interquartile of 0.2 to 0.9 µg/L.
To be able to interpret biomonitoring data, it is important to have
information on the toxicokinetics of the biomarkers of exposure of in-
terest. While the toxicokinetics of BPA has been largely documented in
humans (Fisher et al., 2011; Teeguarden et al., 2015; Thayer et al.,
2015), only a limited number of human toxicokinetic studies of BPS has
been performed to date (Liu and Martin, 2019; Oh et al., 2018). Some
animal studies have also been conducted (Gayrard et al., 2019a;
Gayrard et al., 2019b; Gingrich et al., 2019; Gingrich et al., 2018;
Grandin et al., 2018). The determination of the toxicokinetics of BPS
and its glucurono-conjugate BPSG in humans is important given the
potential animal-to-human differences in the kinetics. Oh et al. (2018)
documented the time courses of BPS (free BPS and total BPS) in the
plasma and urine of seven male and female Korean volunteers from
Seoul orally exposed to 8.75 µg BPS-d4/kg body weight (bw). In this
study, BPSG was not directly measured; it was rather derived from the
difference between unconjugated BPS analyzed without enzymatic hy-
drolysis and the sum of unconjugated and glucurono-conjugated BPS
(and possibly sulfo-conjugates) measured after enzymatic hydrolysis
with β-glucuronidase solution with some arylsulfatase activity. Karrer
et al. (2018) developed a physiologically-based pharmacokinetic model
for BPA and extrapolated it to its analogs including BPS by (i) de-
termining chemical-specific partition coefficients (tissue-to-serum) with
a quantitative structure-activity relationship (QSAR) approach and (ii)
metabolism parameters with an in vitro assessment of glucuronidation
of BPS in human liver and intestinal microsomes. The model was then
calibrated with the data of Oh et al. (2018). Some model adjustments
had to be made to obtain a good fit to the available human kinetic data;
according to these authors, the modeled higher plasma concentrations
of unconjugated BPS after peroral exposure might be explained by a low
glucuronidation rate.
The objective of the present work was to conduct a clinical study to
compare, within a same framework, the kinetic profiles of un-
conjugated BPS and its specifically quantified BPSG conjugation pro-
duct in female volunteers of childbearing age exposed orally and der-
mally to deuterated BPS (BPS-d8) in controlled conditions. This study
aimed to further contribute to provide basic kinetic data that can serve
to develop a human toxicokinetic model allowing reconstruction of
absorbed doses from biomarkers measurements of specifically mea-
sured BPS and BPSG in vulnerable populations, such as pregnant
women.
2. Materials and methods
2.1. Study design and Ethics approval
A clinical study was conducted to document the kinetics of BPS and
its glucurono-conjugate BPSG specifically in plasma and urine of female
subjects of childbearing age following a single oral and dermal exposure
to BPS. The same volunteers (with the exception of three individuals)
were exposed orally and then dermally one month later, to ensure
complete elimination of the compound between exposures. The study
protocol and consent form were approved by the Clinical Research
Ethics Committee (CERES) of the University of Montreal prior to study
onset (certificate number 17-153-CERES-P). Each participant gave its
written consent to participate, was informed of the risks of participating
and its right to withdraw from the study at any time. Each participant
received a monetary compensation for its time. Volunteers spent the
first sampling day at the University for blood and urine sampling and
were then asked to return the next three mornings for a blood sampling
and to return urine samples. Two accredited nurses were present during
the whole study period, performed blood sampling and monitored signs
and symptoms.
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2.2. Volunteers and dosing
Eight adult female volunteers – in good health, aged between 21 and
30 years old and weighing between 55.5 and 88.9 kg (mean of 65.5 kg)
– were recruited on a voluntary basis, seven of which participated in the
oral exposure and six in the dermal application. Each of seven volun-
teers was administered a single oral dose of BPS-d8 (4,4′-sulfonylbi-
sphenol-d8, purity > 99%, isotopic purity > 98%, MW of 258.32 g/
mol, Toronto Research Chemicals, Toronto, Canada) of 0.1 mg/kg of
body weight (bw) (corresponding to 7 mg for an individual of 70 kg or
0.39 µmol/kg bw). The dose administered orally to volunteers, in the
deuterated form, is identical on a mass basis to that previously used in a
kinetic study in volunteers exposed orally to BPA (0.1 mg/kg BPA-d6)
and close on a molar basis (0.43 µmol/kg bw) (Thayer et al., 2015).
This dose is 100 times lower than the No-Observed Adverse Effect
Level (NOAEL) for a subchronic exposure (USEPA, 2014). The NOAEL
was established from a 45-day toxicity study in adult male rats orally
exposed to BPS. For the parental toxicity, the NOAEL dose was estab-
lished at 10 mg/kg bw and the Lowest-Observed-Adverse-Effect-Level
(LOAEL) dose was established at 60 mg/kg bw/day. For the re-
productive toxicity, NOAEL and LOAEL values of 60 and 300 mg/kg
bw/day were established (USEPA, 2014). In the present study, the dose
administered, which is 100 times lower than the NOAEL, considers an
inter-species uncertainty factor (UFA) of 10 and interindividual un-
certainty factor (UFH) of 10.
For the oral administration, BPS-d8 was dissolved in ethanol
(100 mg/mL equivalent to 10 mg/100 μL) and the solution was applied
on a cookie (70 μL of solution on a cookie for a 70-kg individual). The
ethanol deposited on the cookie was left to evaporate for 10 min prior
to ingestion by each volunteer. Each participant then drank 100 mL of
water.
One month after the oral exposure, volunteers were exposed der-
mally to an acute dose of BPS of 1 mg/kg bw. It is important to note that
there is currently no recommended reference dose for dermal exposure.
Studies on the toxicokinetics of bisphenol A (BPA) in animals and hu-
mans estimated that the absorption fraction was 8.6 ± 2.1% in human
skin explants (n = 7) (Demierre et al., 2012). To establish the dermally
applied dose, it was considered that dermal absorption was < 10%,
based on the study by Demierre et al. (2012) and therefore it was set 10
times higher than the oral dose. About 48 h before dermal application
of BPS, participants were recommended to remove hair on their
forearm while taking care not to irritate the skin. The solution was then
applied to an area of 40 cm2 of the forearm delimited by an indelible
marker. BPS was suspended in a 0.1 M phosphate buffer (pH 7.4)
containing 1% sodium carboxymethylcellulose of medium viscosity
(100 mg/mL or 100 μg/μL) (a synthetic gel used against dry eye and as
a food additive) and applied as drops (700 μL for an individual of
70 kg). The treated area was left uncovered and unwashed for a period
of 6 h. After 6 h of dermal contact, a wipe was used (Hines et al 2017) to
clean the entire application area. The application site was then washed
with soap and water. The duration of application of 6 h was chosen to
represent the normal duration of exposure of an employee handling
receipts and to take into account the constraints related to protecting
the application area. Furthermore, it was decided not to occlude the
application area to prevent the transfer of the product on occlusion
material.
2.3. Blood and urine sampling
The time-courses of the parent product BPS-d8 and its glucurono-
conjugate BPSG-d8 in plasma were established by performing serial
blood sampling by venipuncture on the arm 30 min before exposure
(corresponding to a control sample) and at fixed time periods over 48 h
following exposure, i.e. at 15 min, 30 min, 45 min, 1 h, 1 h 15, 1 h 30,
1 h 45, 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 24 h and 48 h post-dosing
(n = 17 samples per individual). In order to facilitate blood sampling, a
catheter was placed during the first sampling day. Blood was collected
in heparin tubes.
For the cutaneous application, the catheter was installed at the level
of the ulnar vein of the arm contralateral to that on which the BPS-d8
was applied. Samples were taken by repeated venous punctures at
previously fixed times. A volume of 10 mL was taken at each sampling
time for a total of 170 mL, which is less than a donation of blood.
In parallel, in order to document the urinary excretion time courses
of BPS-d8 and BPSG-d8, complete urine voids were collected in separate
and clearly identified Nalgene® bottles (group, individual, time) at fixed
periods, namely a nocturnal collection before exposure (-10 h-0 h) and
0–2 h, 2–4 h, 4–6 h, 6–8 h, 8–10 h, 10–12 h, 12–14 h, 14–24 h, 24–48 h
and 48–72 h post-administration (n = 11 collections per individual and
all urine voided during an established period was combined to the same
bottle). Participants were asked to drink plenty of water on the day of
exposure (1.5 L per day) to allow frequent urine collections. A 1.5 L
bottle of drinking water was given to each participant on the first
sampling day.
2.4. Treatment of samples and analysis
Immediately after collection, blood samples were stored at 4 °C in
the refrigerator. Within the hour following blood withdrawal, plasma
was isolated by centrifuging samples for 10 min at 1500 g at 4 °C. Four
aliquots of 1 mL were prepared in polypropylene tubes with Fischer
screw cap of 2 mL and then samples frozen at −20 °C. Two aliquots
were shipped one dry ice at INRA in Toulouse for analysis of BPS-d8
and BPSG-d8.
Urine samples were stored in the refrigerator at 4 °C immediately
after collection the first day of sampling or kept in coolers with ice
packs afterwards by participants until they were brought to the
University. Urine volumes were measured the day of collection. For
each sample, 3 aliquots of 3 mL were prepared in 5 mL polypropylene
tubes and 1 aliquot was prepared of 90–100 mL in a 120 mL Sarstedt
container. Samples were subsequently frozen at −20 °C until analysis.
Aliquots were shipped on dry ice for analysis at INRA in Toulouse.
Plasma and urine samples were assayed with an on-line solid phase
extraction (SPE) ultra-performance liquid chromatography coupled to
tandem mass spectrometry (Acquity-2D UPLC® Xevo® TQ, Waters,
Milford, MA, USA). BPS-d8, BPSG-d8, BPSG (used as internal standard)
were purchased from Toronto Research Chemicals and BPS was ob-
tained from Merck KGaA, Darmstadt, Germany. All these standard pu-
rities were higher than 97% and isotopic purities were higher than 98%.
Urine samples collected after oral administration were simultaneously
quantified according to the method previously validated and published
(Grandin et al., 2017; Grandin et al., 2018). Briefly, 100 µL of urine
samples were diluted with 200 μL of acetonitrile/zinc sulfate containing
BPS and BPSG as internal standard (100 ng/mL and 1000 ng/mL). The
centrifuged mixture was loaded onto the on-line C8 cartridge for clean-
up, separated on a CSH C18 column (Acquity 100 × 2.1, 1.7 µm,
Waters) and detected in negative electrospray ionization (ESI-) using
multiple reaction monitoring (MRM) mode. The urine samples collected
after dermal administration and all the plasma samples were assayed as
described in a previous study with minor modifications (Rancière et al.,
2019). Briefly, samples were extracted on ion exchange SPE cartridges
(HR-XAW, Macherey Nagel, Hoerdt, France) and labelled with dansyl
chloride. The dansylated BPS-d8 and BPSG-d8 were loaded onto the on-
line C8 SPE cartridge and separated on a Phenyl Hexyl column (Acquity
100 × 2.1 mm; 1.7 µm, Waters) with a water/acetonitrile gradient
(both eluents containing 0.1% formic acid) [0.3 mL/min, 40 °C]. Ana-
lytes were detected by mass spectrometry after electrospray ionization
in positive mode. The MRM transitions used for the quantification of
dansylated BPS-d8 and BPSG-d8 were 725 > 171 and 668 > 171,
respectively (see Table S1 for structures and fragmentations). The
method was validated in plasma according to the European Medicine
Agency Guidelines from 0.05 to 10 ng/mL (i.e. 0.2 to 39 nM) for BPS-d8
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using a linear model weighted by 1/X (X = concentration) and from 0.5
to 100 ng/mL (i.e. 1.15 to 230 nM) for BPSG-d8 using a linear model
weighted by 1/X2. Blank samples were used to check the absence of
contamination during assays. The accuracy and the intra- and inter-day
precisions (assessed by the coefficients of variation, CV%) of the
method were evaluated from quality control samples at three con-
centration levels (0.08, 0.8 and 8 ng/mL). The CV% were below 17%
for BPS-d8 and 9% for BPSG-d8 with accuracy ranging from 80% to
96% for both molecules. The lower limits of quantification (LLOQ) were
estimated in plasma at 0.05 and 0.5 ng/mL (i.e 0.2 and 1.15 nM) and in
urine at 0.5 and 5 ng/mL (i.e. 2 and 11.5 nM) for BPS-d8 and BPSG-d8,
respectively. The LLOQ values were determined with 5 replicates at the
lowest concentration that can be quantified with an accuracy ranging
from 80% to 120% and an intraday precision lower than 20%. The
limits of detection were estimated at 0.02 and 0.14 ng/mL (i.e. 0.08 nM
and 0.32 nM) in plasma for BPS-d8 and BPSG-d8, respectively.
2.5. Toxicokinetic analysis
Following ingestion, the plasma concentration-time courses of BPS-
d8 and BPSG-d8 showed three phases, a phase of appearance in plasma
followed by a biexponential decrease in concentrations. The different
rate constants for each of the three phases were determined by least-
square fit adjustments of the following general function (Eq. (1)) to
observed individual plasma concentration-time profiles of BPS-d8 and
BPSG-d8 following oral administration of BPS-d8, by using “curve fit-
ting” tool in Matlab. Apparent appearance and biphasic elimination
phases were represented by: C(t) = Ae−αt + Be−βt + Ce−γt (Eq. (1)),
where i) C (t) is the plasma concentration as a function of time; ii) A, B
and C are the preexponential coefficients; iii) α, β and γ are the hybrid
rate coefficients for the three phases. Apparent half-life (t1/2) values
were calculated using the equation t1/2 = 0.693/k where k = α, β or γ
(Hayes, 2007). For the cutaneous exposure, there were too many un-
detectable values to allow such determinations.
From plasma concentration (C) - time profiles after oral exposure,
other calculated parameters include maximal concentration (Cmax),
time-to-peak levels (Tmax), the discrete version of the area under the
concentration-time curve (AUC), the area under the first moment of
concentration-time curve (AUMC), the mean residence time (MRT), the
apparent oral clearance (Cloral), estimated bioavailability (F) and the
systemic plasma clearance (Clplasma) (Gibaldi and Perrier, 1982; Hayes,
2007; Weiss, 1990). Equations used to calculate these parameters are:
∑= − +
∀
− −AUC t t C t C t
1
2
( )[ ( ) ( )]oral
i
i i i i1 1
∑= − +
∀
− − −AUMC t t t C t t C t
1
2
( )[ ( ) ( )]oral
i
i i i i i i1 1 1
Fig. 1. Concentration-time courses of BPS-d8 (A) and BPSG-d8 (B) in the plasma of volunteers (nmol/L) following a single oral administration of 0.1 mg/kg bw
(0.39 µmol/kg bw) of BPS-d8 (mean ± SD) (n = 6). Symbols represent mean values and vertical bars are standard deviations.
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where Dose is the administered dose.
Bioavailability (fraction of BPS-d8 reaching the systemic circulation
unchanged) was indirectly estimated from Cloral using the following
equation (Gibaldi and Perrier, 1982):
=
+
F Q
Q Cloral
where Q is the hepatic blood flow rate (considered here at 25 mL/kg
bw/min).
This equation assumes that first pass metabolism only occurs in the
liver (i.e. no metabolism in the gastrointestinal tract) and that BPS-d8 is
completely absorbed from the gut lumen after oral dose (i.e. that the
oral absorption fraction fabs is 1; not to be confused with the bioavail-
ability), given that by default F = 1 – ER, where ER is the extraction
ratio due to first-pass metabolism.
The systemic plasma clearance was therefore deduced from BPS-d8
bioavailability and according to Gibaldi and Perrier (1982) and Weiss
(1990) as follows:
=
×
= × =
+
=
+
×
Cl F Dose
AUC
F Cl Q Q
1 1
plasma
oral
oral
oral Q
Cl
AUC Q
Doseoral
oral
oral
With an absorption fraction< 1, lower Clplasma values would be
obtained.
3. Results
3.1. Time courses of BPS-d8 and BPSG-d8 in plasma after oral
administration
The concentration-time courses of BPS-d8 and BPSG-d8 in plasma
over a 48-h period following oral administration of 0.1 mg/kg bw of
BPS-d8 in volunteers are presented in Fig. 1 (and Fig. S1). Calculated
toxicokinetic parameters determined from the plasma concentration-
time courses are compiled in Tables 1 and 2. While BPSG-d8 was found
in higher concentrations than BPS-d8 (roughly 2-fold based on peak
levels), it is readily apparent that the plasma profiles of BPS-d8 and
BPSG-d8 over 48 h evolved in parallel, and showed rapid appearance
and elimination phases. Apparent appearance rates (mean ± SD)
calculated from the time courses of BPS-d8 and BPSG-d8 were
2.3 ± 2.3 and 1.4 ± 2.3 h−1 (translating into t1/2α of 0.3 ± 0.3 and
0.5 ± 0.3 h), respectively. Average peak values (± SD) were reached
at about the same time for both compounds, that is at 0.7 ± 0.1 and
1.1 ± 0.4 h postdosing, respectively. From the terminal phase of BPS-
d8 and BPSG-d8 in plasma, average (± SD) apparent elimination half-
lives (t1/2γ) of 7.9 ± 1.1 and 9.3 ± 7.0 h were calculated, respec-
tively. Similarities in the time courses of BPS-d8 and BPSG-d8 in plasma
(appearance and elimination rates) are also reflected by the same cal-
culated mean residence time (MRT) value of both compounds (as cal-
culated from AUMC
AUC
). The fraction of BPS reaching the systemic circu-
lation unchanged (i.e. bioavailability) was further calculated at
62 ± 5% on average (± SD) (with an Cloral of 0.94 ± 0.19 L/kg bw/
h) and the systemic plasma clearance was estimated at 0.57 ± 0.07 L/
kg bw/h. Furthermore, from the individual time-courses of BPS-d8 and
BPSG-d8 in plasma, the curve showing small plasma peak concentra-
tions around 4–10 h is compatible with an enterohepatic recirculation
(see supplementary Fig. S1).
3.2. Time courses of BPS-d8 and BPSG-d8 in urine after oral administration
The time courses of BPS-d8 and BPSG-d8 excretion rate in the urine
of volunteers over the 72-h period following ingestion of 0.1 mg/kg bw
of BPS-d8 are depicted in Fig. 2. Urinary excretion rate profiles ap-
peared to evolve in parallel for both substances and were similar to
plasma profiles, as expected.
The time courses of BPS-d8 and BPSG-d8 cumulative excretion over
the 72-h period post-administration were also derived (Fig. 3 and Fig.
S2). Although the urinary excretion time courses of BPS-d8 and BPSG-
d8 were similar, BPSG-d8 was present in ≈30-times higher amounts
Table 1
Mean (± SD) time to peak levels, first-order apparent appearance and elim-
ination half-lives and excretion fraction derived from individual time courses of
BPS-d8 and BPSG-d8 in the plasma and urine of volunteers following ingestion
of 0.1 mg/kg bw of BPS-d8 (n = 6 in plasma and n = 7 in urine).
Mean ± SDa
(n = 6 in plasma and n = 7 in urine)
BPS BPSG
Plasma Urine Plasma Urine
Time-to-peak levels Tmax
(h)b
0.7 ± 0.1 1.1 ± 0.4
Maximal concentration
Cmax
(nmol/L)b
158 ± 47 273 ± 127
Apparent appearance t1/
2α
(h)
0.3 ± 0.3 0.5 ± 0.3
Apparent elimination t1/
2β
(h)
1.0 ± 0.6 1.0 ± 0.8
Apparent terminal
elimination t1/2γ
(h)
7.9 ± 1.1 9.3 ± 7.0
Excreted fraction
(molar % of total
dose)c
1.7 ± 1.3d 54 ± 10d
a Represents mean ± SD values of kinetic parameters derived from in-
dividual time course data.
b Mean time-to-peak levels and maximal concentration (± SD) were calcu-
lated from peak values observed for each individual.
c Represents the molar percentage of total administered dose of BPS-d8 re-
covered in urine as BPS-d8 and BPSG-d8.
d Range of values of 0.6–4.4% for BPS-d8 and 37–72% for BPSG-d8.
Table 2
Toxicokinetic parameters calculated from plasma concentration-time profiles of
BPS-d8 and BPSG-d8 (on a molar basis) in volunteers following ingestion of
0.1 mg/kg bw of BPS-d8 (n = 6).
Toxicokinetic parameters Mean ± SD (n = 6)
BPS-d8 BPSG-d8
AUC0→∞ oral
(nmol/L × h)
432 ± 89 946 ± 345
AUMCoral
(nmol/L × h2)
3082 ± 886 6774 ± 3852
MRT
(h)
7.1 ± 1.0 6.9 ± 2.6
Cloral
(L/kg bw/h)
0.94 ± 0.19 0.45 ± 0.13
Bioavailability (F)
(%)a
62 ± 5
Clplasma
(L/kg bw/h)b
0.57 ± 0.07
a Bioavailability (F) corresponds to the fraction of BPS-d8 reaching the sys-
temic circulation unchanged. This calculation (to be valid) assumes that the
oral absorption fraction (fabs) is 1 given that by default F = 1 – ER, where ER is
the extraction ratio due to first-pass metabolism that is considered to occur only
in the liver.
b Clplasma was computed from Cloral and the estimated bioavailability (F).
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than BPS-d8. The average percent (± SD) of the administered dose
recovered in urine as BPS-d8 and BPSG-d8 over the 0–72 h period
postdosing was 1.72 ± 1.3 and 54 ± 10%, respectively (with a range
of 0.6–4.4 and 37–72%, respectively; Table 1). Urinary excretion ap-
pears near complete after 72 h (asymptote being reached at 72 h).
3.3. Time courses of BPS-d8 and BPSG-d8 in plasma after cutaneous
application
The individual time courses of BPS-d8 and BPSG-d8 in plasma over
a 48-h period following the onset of a 6-h cutaneous application of
1 mg/kg bw of BPS-d8 in volunteers are displayed in Table S2. Values
were under the lower limit of quantification (LLOQ) for most time
points such that average time course were not reported (Hecht et al.,
2018). With such low levels, it was not possible to determine tox-
icokinetic parameters, as was done for oral exposure. Nevertheless, an
increase in plasma levels of both compounds was detectable from in-
dividual profiles and peak values were reached between 5 and 8 h
depending on individuals, which is close to the time of cleaning of the
treated area. BPSG-d8 was also found in somewhat higher molar con-
centrations than BPS-d8 (roughly 2- to 9-fold at peak levels).
3.4. Time courses of BPS-d8 and BPSG-d8 in urine after cutaneous
application
In line with blood profiles, limited amounts of BPS-d8 and its con-
jugate were recovered in urine after cutaneous application and peak
excretion rates were reached between 5 and 11 h postdosing depending
on the volunteer while mean value shows a peak at 1 h (Fig. 4). BPSG-
d8 appears to be excreted somewhat more slowly than BPS-d8 over the
72-h collection period, but again values were close to the LLOQ, such
that this should be interpreted with caution. The cumulative excretion
time courses of BPS-d8 and BPSG-d8 show that BPSG-d8 is excreted in
about 20-times higher amounts than BPS-d8, and that excretion is not
totally complete after 72 h (lack of asymptote) at least for part of the
volunteers (Fig. 5 and Fig. S3). The average percent (± SD) of the
administered dose recovered in urine as BPS-d8 and BPSG-d8 was about
0.004 ± 0.003 and 0.09 ± 0.07%, respectively. This suggests a rather
low relative bioavailability by the cutaneous route when compared to
the oral route.
Fig. 2. Time courses of BPS-d8 (A) and BPSG-d8 (B) excretion rate in the urine (% dose/h) of volunteers following a single oral administration of 0.1 mg/kg bw of
BPS-d8 (mean ± SD) (n = 7) (B). Symbols represent mean values and vertical bars are standard deviations.
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4. Discussion
4.1. Toxicokinetics of BPS in humans after oral exposure
There are limited data on the toxicokinetics of BPS to date. This is
the first study to document the toxicokinetics of BPS and BPSG speci-
fically following dermal and oral exposure in volunteers within a same
experimental framework, and complements the available oral kinetic
data of Oh et al. (2018) and dermal data of Liu and Martin (2019).
Female volunteers of childbearing age were chosen for our study, given
that the acquired data aimed to serve, in a next step, for the develop-
ment of a human toxicokinetic model allowing reconstruction of ab-
sorbed doses from measurements of BPS and BPSG in the plasma and/or
urine of vulnerable populations, such as pregnant women. Deuterated
compound was administered (BPS-d8) to ensure that measured levels in
plasma and urine were not partially due to a body burden resulting
from environmental exposure to BPS (Andra et al., 2016; Thayer et al.,
2015). Oh et al. (2018) recently documented the plasma and urinary
time courses of unconjugated and total BPS; BPSG levels were estimated
by the difference between total BPS and unconjugated BPS levels. In the
current work, BPS-d8 and BPSG-d8 were quantified specifically by
UHPLC-MS-MS.
Plasma profile and urinary rate time course obtained in our study
after oral exposure to a single low-dose show the rapid appearance of
BPS in plasma and elimination from the body of volunteers (elimination
t1/2 from the terminal phase in plasma of ≈7.9–9.3 h on average),
mainly in the conjugated form (see Table 1 and Figs. 1 and 2). The
similar apparent initial rate of BPS-d8 and BPSG-d8 after oral exposure
suggests that both forms reach the systemic bloodstream at about the
same time period, indicative of a rapid conjugation of BPS-d8 in in-
testines/enterocytes or liver prior to reaching the systemic circulation
(first-pass effect). This has also been suggested from toxicokinetic stu-
dies of BPS in pigs (Gayrard et al., 2019a; Gayrard et al., 2019b), but
also by Karrer et al. (2018) who developed a physiologically-based
pharmacokinetic (PBPK) model for BPA and adapted the model to other
analogues, such as BPS. These authors suggest that first-pass glucur-
onidation occurs mainly in the liver rather than in enterocytes.
The elimination time course of BPSG-d8 in plasma after oral ex-
posure was also similar to that of BPS-d8 (see Fig. 1 and Tables 1 and 2).
The observed plasma kinetic features further suggest that the most
important contribution to the overall elimination rate of BPS from
blood is phase II conjugation to form more polar moieties, given the
Fig. 3. Time courses of BPS-d8 (A) and BPSG-d8 (B) cumulative excretion (as a molar % of administered dose) in the urine of volunteers following a single oral
administration of 0.1 mg/kg bw of BPS-d8 (mean ± SD) (n = 7). Symbols represent mean values and vertical bars are standard deviations.
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very small levels of unconjugated compound in urine. On the other
hand, elimination of BPSG through excretion contributes mainly to
BPSG overall clearance from blood. Furthermore, the observed time
profiles of BPS-d8 and BPSG-d8 in plasma (behaviour at 6–10 h in
particular) is indicative of a significant entero-hepatic recycling as was
reported in rats (Gayrard et al., 2019b) and from the modeling of BPA
in humans (Karrer et al., 2018). Although bisphenol conjugates are
rapidly formed, the high levels of β-glucuronidase and arylsulfatase in
tissues such as the liver, kidneys and placenta should allow deconju-
gation to the active unconjugated form, and in the case of intestines
bacterial enzymes favors reabsorption from the gut lumen (Andra et al.,
2016; Beaud et al., 2005; Danovitch and Laster, 1969; Parkinson et al.,
2012).
From the plasma-concentration time course in volunteers of our
study, a systemic plasma clearance (Clplasma) of BPS of 0.57 ± 0.07 L/
kg bw/h and an oral bioavailability of 62 ± 5% were estimated (see
Table 2), provided that the following two assumptions are met: i) oral
absorption of BPS was total and ii) BPS is only eliminated by hepatic
metabolism, which is consistent with a very low renal clearance of BPS.
The plasma clearance as obtained in the current study is rather close to
the human plasma clearance value of 0.79 L/kg bw/h inferred by al-
lometric extrapolation from toxicokinetic data in rats, ewes and piglets
(Gayrard et al., 2019a), thus confirming these results.
In our study, the total percentage of the administered molar dose
recovered in urine as unconjugated BPS-d8 following oral exposure was
similar to that observed in the study of Oh et al. (2018), with a range of
0.6 to 4.4% in our study compared to 0.9 to 3.3% in female volunteers
of the study of Oh et al. (2018), indicating that the renal clearance of
unconjugated BPS-d8 was low. However, with regard to cumulative
excretion of BPSG-d8 in urine, somewhat lower excretion values were
found in volunteers of our study. More specifically, our individual re-
sults show that 37 to 72% of the administered oral dose were recovered
in urine as BPSG-d8 over the 0–72 h collection period postdosing, de-
pending on the volunteers; when excluding the volunteer with the
lowest cumulative excretion in urine, the observed total urinary ex-
cretion ranged between 51 and 72%, suggesting that clearance of BPS-
d8 is mainly driven by its glucuronidation. In the study of Oh et al.
(2018), the reported total percentage of the oral dose recovered in urine
as BPSG (total BPS minus unconjugated BPS) varied between 59 and
77% in the female participants (n = 3), with a mean value of 70%, i.e.
in the same order of magnitude as that observed in our study. In the
male participants of that study, corresponding range of values was
67–104%, with a mean of 92% (n = 4). Differences between our results
and those of Oh et al. (2018) may partly be explained by the fact that
Fig. 4. Time courses of BPS-d8 (A) and BPSG-d8 (B) excretion rate in the urine (% dose/h) of volunteers following a cutaneous application of 1 mg/kg bw of BPS-d8
during 6 h (n = 6). Symbols represent mean values and vertical bars are standard deviations.
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the latter account for BPS conjugated to sulfates (even if reported sul-
fatase enzyme activity was low), given that conjugated BPS was esti-
mated by the difference between total BPS and unconjugated BPS. In
our work, the glucurono-conjugate was rather measured specifically.
Other studies in the general population confirmed the presence of sul-
fate conjugates of bisphenol analogues in urine (Andra et al., 2016;
Gerona et al., 2016; Liao and Kannan, 2012; Liu and Martin, 2019), and
there is a known polymorphism between men and women in uridine-
diphosphate (UDP)-glucuronosyltransferase (UGTs), in addition to
ethnical variations (Gallagher et al., 2010; Iwai et al., 2004; Kojima and
Degawa, 2014; Lampe et al., 2000; Mazur et al., 2010; Mehboob et al.,
2017; Sparks et al., 2004). In particular, Gerona et al. (2016) reported
that 15% of BPA forms recovered in the urine of the monitored in-
dividuals from the general population (pregnant women of diverse
ethnic background) were sulfate conjugates. Karrer et al. (2018) con-
sidered that bisphenols are conjugated to sulfates in their model, but to
a lesser extent than glucurono-conjugates. In an in vitro study in human
HepaRG hepatic cell line, Le Fol et al. (2015) found that 85.8% of BPS
was conjugated to glucuronides and 10.5% to sulfates. In the present
study, the volunteers were of different origins (4 North American
Caucasians, 3 of North African Arabic origin). Furthermore, in both our
study and the study of Oh et al. (2018), total recovery of the different
BPS forms in urine was less than 100%, suggesting the remaining is
either i) excreted in feces as observed in animals, although the
threshold molecular weight for biliary excretion is higher in humans
than animals (325 ± 50 g/mol for rats and 500 ± 50 g/mol for
humans) (Waidyanatha et al., 2018; Yang et al., 2009) or ii) forms other
metabolites, such as hydroxylated BPS in the ortho- and meta-positions
of the phenol rings (Skledar and Mašič, 2016; Skledar et al., 2016). The
possible polymorphisms and variability in the urinary excretion of BPS
forms in urine is an important aspect to consider for the biomonitoring
of exposure to BPS and interpretation of biomonitoring data.
4.2. Comparison of BPS and BPA toxicokinetics in humans after oral
exposure
The rates of appearance and elimination calculated from the time
courses of BPS-d8 and BPSG-d8 in plasma (Table 1) were similar to
those reported by Thayer et al. (2015) based on serum profiles of un-
conjugated BPA-d6 and total BPA-d6 in volunteers orally exposed to
Fig. 5. Time courses of BPS-d8 (A) and BPSG-d8 (B) cumulative excretion (as a molar % of administered dose) in the urine of volunteers following a cutaneous
application of 1 mg/kg bw of BPS-d8 during 6 h (n = 6). Symbols represent mean values and vertical bars are standard deviations.
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BPA-d6 (mean initial t1/2 (± SD) of 0.52 ± 0.28 and 0.26 ± 0.11 h,
respectively; corresponding elimination t1/2 from the terminal phase of
5.6 ± 1.2 h and 6.4 ± 2.0, respectively). However, concentrations of
unconjugated BPS-d8 at peak levels (Cmax of 158 ± 57 nmol/L) were
found in much higher proportion compared to those of BPA-d6 (Cmax of
6.5 ± 3.2 nmol/L) and AUC0→∞ of unconjugated BPS-d8 was on
average 19 times higher than that of BPA (23 ± 6.2 nmol/L × h) for a
similar administered molar dose (0.39 µmol BPS-d8/kg bw versus
0.43 µmol BPA-d6/kg bw) (see Table 2 for BPS-d8 values in our study).
Furthermore, on average, molar percent of the administered dose ex-
creted in total as BPS-d8 and BPSG-d8 in the urine of volunteers was
1.72 ± 1.3 and 54 ± 10%, respectively, while values of 0.11 ± 0.19
and 87% ± 6.9% were observed for BPA-d6 and BPAG-d6 after oral
dosing with BPA-d6 in volunteers (Thayer et al., 2015). This suggests
that the active unconjugated form of BPS is more prevalent than that of
BPA in humans.
Although there are known animal-to-human differences in the glu-
curonidation, Gayrard et al. (2019b) showed that a significant fraction
of BPS dose in orally exposed piglets reached the systemic circulation in
the unconjugated form (57.4% on average). On the other hand, BPA
underwent a significant first-pass phase II metabolism to BPAG after
oral exposure such that, on average, only 0.5% of the administered dose
was found unconjugated in plasma. These authors also found that
plasma clearance of BPS was 3.5 times lower than that of BPA. From the
piglet data, a toxicokinetic model was also developed by these authors
and predicted that virtually all (99%) of BPS oral dose was absorbed as
compared to about 77% on average for BPA. Their model also suggested
that BPS conjugation did not occur in enterocytes but rather in the liver
(44% of absorbed fraction) contrary to BPA for which an extensive first-
pass glucuronidation in the gastrointestinal (GI) tract (44%) and liver
(99% of the BPA that did not undergo conjugation in enterocytes) was
simulated. In turn, systemic bioavailability of active unchanged BPS
was estimated to be 57.4% versus 0.5% for BPA in piglets. Our human
data on BPS compared to those of Thayer et al. (2015) also suggest a
difference in the kinetics of BPS and BPA (in particular in the glucur-
onoconjugation).
4.3. Toxicokinetics of BPS after dermal exposure and comparison with BPA
Dermal time course values were too close to the limit of detection or
quantification to provide a direct comparison with the oral kinetic data.
Nonetheless, as observed following oral exposure, our results also show
that BPS is very rapidly absorbed in the systemic circulation and
eliminated from the body following dermal application of a low dose;
however, elimination did not appear to be complete after 72 h, sug-
gesting a somewhat longer residence time after dermal than oral ex-
posure. Similarly, Liu and Martin (2017) reported that BPA was
eliminated more slowly from the body after dermal contact with
thermal receipts containing BPA compared to dietary exposure; they
also reported that the proportion of unconjugated BPA in the systemic
circulation was higher after dermal exposure than ingestion. In animals,
Gingrich et al. (2019) determined the time courses of total BPS (con-
jugated and non conjugated) in the plasma of pregnant sheep following
subcutaneous exposure of 0.5 mg/kg of BPS and the calculated MRT
(6.7 ± 0.3 h) was very close to that calculated in the current study for
BPS following oral exposure.
Results of our study further highlight that the dermal absorption
fraction is very low, that is < 0.1% based on BPS and BPSG profiles,
which is smaller than that reported for BPA by Demierre et al. (2012)
from human skin explants. In the latter study, on average (± SD),
56.9 ± 4.9% of the applied 14C-BPA remained on the skin surface 24 h
after application on skin explants and 8.6 ± 2.1% were found in the
receptor fluid at 24 h post-application (n = 7 skin membranes prepared
from two skin explants). With an experimental protocol similar to that
of Demierre et al. (2012) but using fresh metabolically-active human
skin explants and different 14C-BPA exposure levels, Toner et al. (2018)
obtained lower recoveries of 14C-BPA in the receptor fluid - translating
in a dermal absorption of 2–4% - and found a certain metabolism in the
skin. More recently, Liu and Martin (2019) compared the percutaneous
absorption and biotransformation of BPS and BPA in vitro using human
epidermal cells (EpiDerm™ EPI-212 tissue constructs, a three-dimen-
sional tissue model consisting of normal human epidermal keratino-
cytes on tissue culture inserts). They found that the permeability
coefficient of BPS was lower than that of BPA. At both doses, < 10% of
total BPS had migrated into the receiver solutions, whereas 43–46% of
total BPA were recovered in receiver solutions (0.003–0.009 cm/h
versus 0.033–0.036 cm/h after application of 1.5 or 7.7 µg/cm2). They
also reported a limited metabolism in the skin, given that more than
70% of total BPS and total BPA were found in the unconjugated form in
skin tissue and in receiver solutions. These authors further compared
the dermal penetration of BPS (not reported to be deuterated) and BPA-
d6 from cumulative urinary excretion in volunteers simulating handling
of thermal receipts and found that free BPS levels in 48-h urine col-
lections, expressed as a proportion of total urine bisphenol, were higher
than free BPA-d6 (6.9 ± 2.8% versus 2.7 ± 1.9%). In line with these
results, the average molar ratio of BPS-d8/(BPS-d8 + BPSG-d8) in the
urine of volunteers of our study can be calculated at 4.3%.
It is to be noted that BPS was applied on the forearm on our study.
Ideally, it would have been better to apply BPS on a hand, which is the
main exposure site, but this is hardly feasible. During biomathematical
modeling, the permeability constant estimated from the data obtained
can be adjusted to take into account the greater permeability of the skin
of the forearm compared to that of the hands. Furthermore, the choice
of the application area (40 cm2) was to allow applying from 10 to
20 μL/cm2 for a body weight between 50 and 70 kg, in accordance with
the OECD (2004) recommendations of 10 μL/cm2. This suspension
applied to an area of 40 cm2 translates into an applied dose of 1.25 to
1.75 mg/cm2 (body weight between 50 and 70 kg), which is in the same
order of magnitude as the maximum dose recommended by the USEPA
(1998) of 1 mg/cm2 to ensure the absence of saturation of the ab-
sorption process. It is also in the same order of magnitude as the
maximum exposure dose of skin estimated for BPA when handling cash
receipts and determined from the maximal transfer coefficient of BPA
(21522 ng/s) and the skin surface area of hands in contact with tickets
(23.5 cm2, i.e. 0.6 mg/cm2) (Bernier and Vandenberg, 2017).
In addition, BPS was applied on the skin in a solution of phosphate
buffer (0.1 M) containing 1% sodium carboxymethylcellulose of
medium viscosity (100 mg/mL) in our study, this medium being re-
commended as it does not modify the permeability of the skin (Vlaia
et al., 2016). Amounts remaining on the skin at 6 h postdosing, hence at
the time of washing, were not quantified. There could be differences in
the absorption rate depending on the dissolution/suspension vehicle. In
particular, dermal absorption rate of BPS through manipulation of
thermal papers (Björnsdotter et al., 2017; Hines et al., 2017; Liu and
Martin, 2017; 2019; Ndaw et al., 2018; Russo et al., 2017) may be
somewhat different from that observed in the current work. In parti-
cular in a study in volunteers manipulating thermal receipts, Hormann
et al. (2014) showed that dermal absorption - as assessed from serum
and urinary levels of BPA, BPAG and sulfo-conjugate of BPA (BPAS) -
was enhanced in individuals who had used hand sanitizers immediately
prior to holding receipts for 45 s compared to when handling receipts
with dry hands. Interestingly, at least one volunteer of that study
showed relatively high BPAS levels.
4.4. Interest of the toxicokinetic data for the purpose of biomonitoring
From a biomonitoring perspective, the data collected in this study
will be used to develop a toxicokinetic model specific to BPS, which will
allow dose reconstruction of BPS from plasma or urinary BPS and BPSG
measurements in exposed individuals. Similar to BPA, the glucurono-
conjugate of BPS is confirmed to be the main form of BPS excreted in
urine and exhibited kinetics similar to the active unconjugated BPS
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moiety in humans with a short half-life. The rather short half-life of
BPS-d8 and BPSG-d8 observed in our study following oral exposure
suggests that steady-state equilibrium should be rapidly reached in
individuals repeatedly exposed by ingestion, but there could be sig-
nificant fluctuations in plasma and urinary concentrations for punctual
BPS exposure through ingestion of contaminated food and drinks.
Furthermore, the dermal data show a limited skin absorption such that
dermal dose must be very high to contribute significantly to the ab-
sorbed dose by multiple routes, that is following combined oral, dermal
and respiratory exposure. However, the apparent longer residence time
of BPS in the body after dermal exposure suggests that a possible ac-
cumulation may be more important after dermal exposure than oral
exposure upon repeated daily exposure.
4.5. Conclusions
Overall, the current data allowed to further document the tox-
icokinetics of BPS in humans. It confirmed the rapid appearance and
elimination of the compound and its conjugate in the systemic circu-
lation following oral exposure, with a majority of the dose being rapidly
converted to the BPSG form. The present data also evidenced major
differences between BPA and BPS kinetics with much higher systemic
levels of active BPS than BPA, an observation explained by a higher oral
bioavailability of BPS than BPA. These data indicate that the replace-
ment of BPA by BPS could lead to increased exposure to a hormonally
active substance. This work also confirmed the limited dermal ab-
sorption of BPS compared to oral absorption, but with a potentially
longer residence time observed from plasma and urinary rate time
courses after dermal exposure. These data should be useful for the de-
velopment of a toxicokinetic model for a better interpretation of bio-
monitoring data. The current kinetic data is limited to a few volunteers
for feasibility and cost reasons; as highlighted by Andra et al. (2016),
future studies are needed to document the variability in phase II con-
jugation between individuals (male, female, pregnancy status), which
may affect interpretation of biomonitoring data.
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